In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck to co-promote Daxas with Nycomed in Europe and Canada; deals ends

Executive Summary

Nycomed International Management GMBH has granted Merck & Co. Inc. rights to market Daxas (roflumilast) for chronic obstructive pulmonary disease (COPD) in certain European countries and Canada.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register